SquareMind Raises $18M Series A for AI Robotic Full-Body Skin Imaging Platform

Paris-based AI and robotics company SquareMind has secured $18 million in Series A funding to advance its Swan platform for full-body dermoscopic skin imaging. The investment will support commercial launch in the U.S. and Europe, accelerating the deployment of AI-powered robotic skin examination technology.

The Swan platform combines advanced robotics with AI algorithms to perform comprehensive skin imaging, enabling early detection of skin cancer and other dermatological conditions. The system provides high-resolution full-body scans with automated analysis capabilities, supporting dermatologists in diagnosis and treatment planning.

Founded in 2022, SquareMind has developed proprietary technology that integrates [computer vision](/glossary/computer-vision), machine learning, and robotic manipulation to deliver clinical-grade skin imaging solutions. The company aims to make skin cancer screening more accessible and accurate through its automated robotic systems.

The funding round will enable SquareMind to expand its team, complete regulatory approvals, and establish commercial partnerships with healthcare providers and dermatology clinics across major markets.